Animal Welfare in Pharmaceutical Testing

Pharmaceutical development requires animal testing under most regulatory frameworks, but welfare improvements through replacement, reduction, and refinement are achievable.

Key Facts

Approximately 192 million animals are used in research globally each year
Pharmaceutical development is the single largest use of animals in research
The 3Rs framework (Replace, Reduce, Refine) guides welfare improvement in pharmaceutical research
Organ-on-chip and organoid technologies are advancing as partial replacements for animal models
Regulatory bodies including the FDA and EMA increasingly accept validated alternative methods

Welfare Considerations

Pharmaceutical animal testing presents a genuine ethical tension - without animal models, medicines that save human and animal lives cannot be safely developed. The welfare imperative is therefore to pursue replacement where scientifically valid, reduction through statistical design improvements, and rigorous refinement to minimize suffering in necessary tests. Significant welfare improvements are achievable without compromising safety: better analgesia, more humane endpoints, refined housing conditions, and adoption of validated alternatives all reduce suffering while maintaining research quality.

What You Can Do

Support NC3Rs, FRAME, and other organizations advancing alternatives to animal testing
Advocate for government funding of 3Rs research
Choose pharmaceutical companies with strong published 3Rs commitments
Support regulatory harmonization that accepts validated alternative methods globally
Learn about the science of animal testing alternatives and share accurate information